Skip to main content
. Author manuscript; available in PMC: 2020 Sep 3.
Published in final edited form as: Adv Drug Deliv Rev. 2019 Sep 3;144:148–161. doi: 10.1016/j.addr.2019.08.010

Figure 8.

Figure 8.

Small-molecule modifications of the alginate backbone can mitigate the FBR. (a) The lead small-molecule modifications that were identified from a combinatorial modified alginate library. These lead modified alginates successfully mitigated fibrosis in the IP space of both immunocompetent murine and NHP animal models. (b) Representative phase contrast imaging of retrieved capsules for the control (SLG20) and modified alginate formulations after 4 weeks in NHP are shown. (c) Immunofluorescence imaging of the retrieved capsules in (b) showed reduced markers of general cellular material (DAPI), myofibroblasts (α-SMA), and macrophages (CD11b). Figure and caption adapted with permission from reference [117].